(5-氯-2-氧代-1,3-苯并噻唑-3(2H)-基)乙酸 | 54769-25-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (5-氯-2-氧代-1,3-苯并噻唑-3(2H)-基)乙酸
• 英文名称: (5-chloro-2-oxo-1,3-benzothiazol-3(2H)-yl)acetic acid
• 英文别名: 2-(5-chloro-2-oxo-1,3-benzothiazol-3-yl)acetic acid
• CAS: 54769-25-4
• 化学式: C₉H₆ClNO₃S
• 分子量: 243.671
• InChiKey: MYTTVLWLGMIDQY-UHFFFAOYSA-N

物化性质

• 熔点：
  250-251 °C(Solv: ethanol (64-17-5))
• 沸点：
  493.4±55.0 °C(Predicted)
• 密度：
  1.627±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  82.9
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P330,P363,P501
• 危险性描述：
  H302,H312,H332

反应信息

• 作为反应物：
  描述：

  (5-氯-2-氧代-1,3-苯并噻唑-3(2H)-基)乙酸 在 氯化亚砜 、 sodium carbonate 作用下， 以 四氢呋喃 、 苯 为溶剂， 反应 3.0h， 生成 4-[(5-chloro-2-oxo-benzothiazol-3-yl)-acetyl]-morpholine
  参考文献：
  名称：

  (5-Chloro-2-benzothiazolinon-3-yl)乙酰胺衍生物的合成及镇痛活性

  摘要：

  报道了（5-氯-2-苯并噻唑啉酮-3-基）乙酰胺衍生物的合成。这些化合物的结构由它们的 IR 和 1H-NMR 光谱支持。测试化合物的镇痛活性。

  DOI：

  10.1002/1521-4184(200010)333:10<337::aid-ardp337>3.0.co;2-a
• 作为产物：
  描述：

  3-(methoxycarbonylmethyl)-5-chloro-2(3H)-benzothiazolone 在 sodium hydroxide 、 盐酸 作用下， 以 甲醇 、 水 为溶剂， 反应 4.0h， 以96%的产率得到(5-氯-2-氧代-1,3-苯并噻唑-3(2H)-基)乙酸
  参考文献：
  名称：

  Process Development of a Platelet Aggregation Inhibitor

  摘要：

  A practical and efficient method for N-amination of piperazine via a nitrosoamine, suitable for a large scale synthesis, is described. This method involved the temporary transformation of an in situ prepared aminopiperazine to a hydrazone, allowing efficient separation of zinc salt byproducts from the system. Acylation and deprotection with hydroxylamine directly afforded FR062732 in satisfactory quality for pharmacological evaluation. These methods solved the operational problems usually inherent in zinc reduction of nitrosoamines.

  DOI：

  10.1021/op980050c

文献信息

• Microwave-Assisted Synthesis of 1,3-Benzothiazol-2(3H)-one Derivatives and Analysis of Their Antinociceptive Activity
  作者：T. Önkol、Y. Dündar、E. Yıldırım、K. Erol、M. Şahin

  DOI：10.1055/s-0032-1327613

  日期：——

  developed for synthesis of 6-acyl-1,3-benzothiazol-2(3H)-one derivatives under microwave irradiation (MWI) conditions. The reaction times were shortened compared to conventional heating. Additionally, we synthesized acetic acid and acetamide derivatives of 1,3-benzothiazol-2(3H)-one, 6-acyl-1,3-benzothiazol-2(3H)-one, 5-chloro-1,3-benzothiazol-2(3H)-one and 6-acyl-5-chloro-1,3-benzothiazol-2(3H)-one with

  开发了一种快速有效的方法，在微波辐射（MWI）条件下合成6-酰基-1,3-苯并噻唑-2（3H）-一衍生物。与常规加热相比，反应时间缩短了。此外，我们合成了1,3-苯并噻唑-2（3H）-一，6-酰基-1,3-苯并噻唑-2（3H）-一，5-氯-1,3-苯并噻唑-的乙酸和乙酰胺衍生物微波辅助法制得2（3H）-一和6-酰基-5-氯-1,3-苯并噻唑-2（3H）-一，并用甩尾，甩尾，加热板和扭绞法分析其抗伤害性测试。在合成的化合物中，3- [2-（4-乙基哌嗪-1-基）-2-氧乙基] -1,3-苯并噻唑-2（3H）-一（6a），5-氯-3- 2-氧代-2- [4-（丙-2-基）哌嗪-1-基]乙基} -1,3-苯并噻唑-2（3H）-一（7e）和3- [2-（4-丁基哌嗪-1） -基）-2-氧代乙基] -5-氯-1，3-苯并噻唑-2（3H）-1（8e）在尾夹，甩尾，热板和扭绞试验中显示出显着的抗伤害感
• HETEROCYCLIC ACETAMIDE COMPOUND
  申请人：ASTELLAS PHARMA INC.

  公开号：US20140315963A1

  公开（公告）日：2014-10-23

  [Problem] A compound which is useful as a dopamine D1 receptor positive allosteric modulator (D1 PAM) is provided. [Means for Solution] The present inventors have studied a compound which has a dopamine D1 receptor positive allosteric modulating activity and is useful as an active ingredient of a pharmaceutical composition for preventing and/or treating cognitive impairment, negative symptoms of schizophrenia, Parkinson's disease, Alzheimer's disease, Huntington's disease, drug addictions, or the like, and they have thus found that a heterocyclic acetamide compound has a dopamine D1 receptor positive allosteric modulating activity, thereby completing the present invention. The heterocyclic acetamide compound of the present invention has a dopamine D1 receptor positive allosteric modulating activity and can be used as an agent for preventing and/or treating cognitive impairment, negative symptoms of schizophrenia, Parkinson's disease, Alzheimer's disease, Huntington's disease, drug addictions, or the like.

  [问题] 提供了一种作为多巴胺D1受体正变构调节剂（D1 PAM）有用的化合物。 [解决方案] 本发明的发明人已经研究了一种具有多巴胺D1受体正变构调节活性的化合物，该化合物作为用于预防或治疗认知障碍、精神分裂症阴性症状、帕金森病、阿尔茨海默病、亨廷顿病、药物成瘾等的药物组合物的有效成分是有用的，他们因此发现了一种杂环乙酰胺化合物具有多巴胺D1受体正变构调节活性，从而完成了本发明。本发明的杂环乙酰胺化合物具有多巴胺D1受体正变构调节活性，并且可以用作预防或治疗认知障碍、精神分裂症阴性症状、帕金森病、阿尔茨海默病、亨廷顿病、药物成瘾等的药剂。
• Sulfonic acid esters
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US04242507A1

  公开（公告）日：1980-12-30

  A novel process for the amidation or esterification which comprises reacting a compound having a carboxy group with a compound having an amino or imino group which can be acylated or with a compound having a hydroxy group in the presence of a sulfonic acid ester of the formula: R.sub.1 --SO.sub.2 --OR.sub.2 wherein R.sub.1 is an organic group and R.sub.2 O-- is a residue of a strongly acidic N-hydroxy compound as a condensation agent, and a novel sulfonic acid ester useful as such a condensation agent and a process for the preparation thereof.

  一种用于酰胺化或酯化的新型过程，包括在有机硫酸酯存在下，将具有羧基的化合物与可酰化的氨基或亚氨基基团的化合物，或具有羟基的化合物反应，其中所述有机硫酸酯的化学式为：R.sub.1 --SO.sub.2 --OR.sub.2，其中R.sub.1是有机基团，R.sub.2 O--是强酸性N-羟基化合物的残基作为缩合剂，以及一种作为这种缩合剂有用的新型磺酸酯和其制备方法。
• MORPHOLINYL AND PYRROLIDINYL ANALOGS
  申请人：Goodman Krista B.

  公开号：US20080021023A1

  公开（公告）日：2008-01-24

  The present invention relates to morpholinyl, and pyrrolidinyl analogs, pharmaceutical compositions containing them, and their use as antagonists of urotensin II.

  本发明涉及吗吗啉基和吡咯啉基类似物，含有它们的药物组合物，以及它们作为尿苷II拮抗剂的用途。
• Heterocyclic acetamide compound
  申请人：Astellas Pharma Inc.

  公开号：US08937087B2

  公开（公告）日：2015-01-20

  [Problem] A compound which is useful as a dopamine D1 receptor positive allosteric modulator (D1 PAM) is provided. [Means for Solution] The present inventors have studied a compound which has a dopamine D1 receptor positive allosteric modulating activity and is useful as an active ingredient of a pharmaceutical composition for preventing and/or treating cognitive impairment, negative symptoms of schizophrenia, Parkinson's disease, Alzheimer's disease, Huntington's disease, drug addictions, or the like, and they have thus found that a heterocyclic acetamide compound has a dopamine D1 receptor positive allosteric modulating activity, thereby completing the present invention. The heterocyclic acetamide compound of the present invention has a dopamine D1 receptor positive allosteric modulating activity and can be used as an agent for preventing and/or treating cognitive impairment, negative symptoms of schizophrenia, Parkinson's disease, Alzheimer's disease, Huntington's disease, drug addictions, or the like.

  [问题] 提供了一种作为多巴胺D1受体正向变构调节剂（D1 PAM）有用的化合物。[解决方案] 现有发明人研究了一种具有多巴胺D1受体正向变构调节活性并且可用作制药组合物的活性成分，用于预防和/或治疗认知障碍、精神分裂症的负性症状、帕金森病、阿尔茨海默病、亨廷顿病、药物成瘾等，因此发现一种杂环乙酰胺化合物具有多巴胺D1受体正向变构调节活性，从而完成了本发明。本发明的杂环乙酰胺化合物具有多巴胺D1受体正向变构调节活性，并可用作预防和/或治疗认知障碍、精神分裂症的负性症状、帕金森病、阿尔茨海默病、亨廷顿病、药物成瘾等的药剂。